Mahamaya Lifesciences IPO Subscription Status
Mahamaya Lifesciences IPO subscribed over 0.34x on its Second day till 05.00 PM on 12th November 2025.
- Mahamaya Lifesciences IPO subscription QIB investors portion is 0.65x times, while NII subscribed 0.27x times, and RII investors subscribed 0.20x times.
- The company has received bids for 14,17,200 shares against 41,17,200 shares on offer on the Second day.
- Mahamaya Lifesciences IPO subscribed over 0.34x times on day 2.
- Mahamaya Lifesciences IPO subscribed over 0.11x times on day 1.
About the Mahamaya Lifesciences IPO
Mahamaya Lifesciences Limited, founded in 2002, is one of the leading companies that focuses on the manufacturing of pesticide formulations and supplies bulk formulations. By working with the Central Insecticides Board and Registration Committee (CIBRC), the company started its business with the import and registration of major pesticide molecules that were not produced in India. After successful registration, they decided to market these molecules as technical products to both Indian agrochemical companies as well as multinational corporations (MNCs).
Since its incorporation in 2002, the company has grown significantly by setting up its own manufacturing plant in December 2021 at Dahej, Gujarat. Its product has reached various states like Punjab, Haryana, Rajasthan, Uttar Pradesh, Gujarat, Maharashtra, Andhra Pradesh, and Telangana in India, while internationally they export their products to Turkey, Egypt, and the UAE.
Mahamaya Lifesciences IPO Company Financial Report
The company reported revenue of ₹267.17 crores in 2025 against ₹162.83 crores in 2024. The company reported a profit of ₹12.94 crores in 2025 against a profit of ₹5.22 crores in 2024.
Mahamaya Lifesciences IPO GMP
Mahamaya Lifesciences IPO GMP was ₹0 as of Wednesday, 12th November. That indicates the IPO is trading at ₹114 with a ₹0 premium in the grey market against the issue price of ₹114.
